@marcriboj

Interventional Neurologist

 Catalonia, Spain
Joined November 2012
  • Tweets82
  • Following145
  • Followers775
9Media
Tomorrow at 9.00 am France time @slice_inr, co-PI's @CostalatV @CarolineArquiz1 @lapergue6 @TudorGJovin will present primary results of LASTE (randomized trial of MT in large core pts. ASPECTS 0-5). Median core = 150 ml with 56% ASPECTS 0-2.Please join us: masterandfellow.com/slice/ww
32
3
117
10,495
Enhorabuena a los ganadores del Premio de la SEN Ictus-2022 Científico: Natalia Perez de la Ossa y Marc Ribó!
6
1
56
4,451
Molt bona defensa de tesi de la, ara ja si, Dra Marta Olivé de la Unitat d’Ictus del nostre servei de #neurologia @vallhebron @NeurocienciesVH @VHIR_ Publicada en Stroke i J Neurointer Surgery. Enhorabona a @mrubifu @carlosmictusvh @marcriboj i a la resta de l’equip!!!
8
1
34
In this RCT, in nonurban areas in Catalonia, Spain, there was no significant difference in 90-day neurological outcomes btwn transportation to a local stroke center vs a thrombectomy-capable referral center in pts w suspected large-vessel occlusion stroke. ja.ma/3LJRkcJ
9
3
22
Patient-reported outcome measures after thrombectomy in patients with acute stroke: fine-tuning the modified Rankin Scale jnis.bmj.com/content/early/2…
1
3
16
Latest in basic science - bit.ly/3MqIcd7 - Li J et al showed up to 79% variability in devices’ tracking performance. Hybrid coil and braid reinforcement configuration and DACs’ distal wall thickness are significant contributory factors to ease navigation. @marcriboj
7
21
Clinical Results of the Advanced Neurovascular Access Catheter System Combined With a Stent Retriever in Acute Ischemic Stroke (SOLONDA) ahajournals.org/doi/10.1161/…

Clinical Results of the Advanced Neurovascular Access Catheter System Combined With a Stent...

Background: The Advanced Neurovascular Access (ANA) thrombectomy system is a novel stroke thrombectomy device comprising a self-expanding funnel designed to reduce clot fragmentation by locally...

ahajournals.org
1
1
11
We are thrilled to have you among us ⁦@IsaRCaamano⁩ your skills will be a great addition to our team! 👏🏻 @VHIR_⁩ ⁦@atomasell⁩ ⁦@marcriboj⁩ ⁦@ManuRequenaRuiz⁩ @vallhebron #neurointerventional #research #talent #future #innovation linkedin.com/posts/marta-de-…

#neurointerventional #neuroscience #research #partnership #teamworking #networking #investinginta...

It is our pleasure to welcome on board Dr. Isabel Rodríguez Caamaño as the new member of the Neurointerventional Research Unit of Vall d’Hebron Hospital Campus Vall d’Hebron Institute of Research...

linkedin.com
5
1
25
Direct to Angiography Suite Without Stopping for Computed Tomography Imaging in Acute Stroke ja.ma/3Cap0fp via @JAMANeuro part of @JAMANetwork Why not DTAS your next case?
2
30
2
88
A mentor’s love for their trainees can be measured in tracked changes
238
1,491
808
12,165
Paving the way towards DIRECT TRANSFER TO ANGIOSUITE in Stroke: First patient WE-TRUST stroke study - News | Philips philips.com/a-w/about/news/a…

Philips announces first patient enrolled in the WE-TRUST global multicenter stroke study to assess...

Philips announces first patient enrolled in the WE-TRUST global multicenter stroke study to assess the impact of the ‘Direct to Angio Suite’ workflow in improving patient outcomes.

philips.com
1
11
41
Dr. Jovin is right, we determined the detrimental effect of additional passes, recanalization with any passes is still better than NO recanalization. When to Stop Detrimental Effect of Device Passes. doi.org/10.1161/STROKEAHA.11…
Tudor G. Jovin, MD@TudorGJovin24 Jun 2021
This proposal reflects flawed logic. Ample evidence exists that # of passes correlate with outcomes BUT also that reperfusion is better than no reperfusion. Outcomes in > 3 pass pts should be compared to non treated patients and not with ≤ 3 pass pts. medpagetoday.com/neurology/s…

Should a 'Three Strikes' Rule Apply to Stroke Thrombectomy?

Reconsider forging ahead with repeated clot retrieval attempts, study suggests

medpagetoday.com
1
6
26
@smartinschild @hariskamalmd @wondeasa @ozmir1 @kaushikparsha @reddy_sujan @ARazzakMD #stroke #NoLVOleftbehind #TimeisBrain – at Houston, TX
1
2
Se han publicado oficialmente los resultado del #BASIC trial Ya hemos hablado harto desde su análisis durante el #ESOWSO2020 No cambiará la práctica x el momento Lo mejor? El nuevo formato de resumen del @NEJM Ps: 👏 Brazilian team nejm.org/doi/full/10.1056/NE…
1
16
56
Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion | NEJM nejm.org/doi/full/10.1056/NE… Inability to show a significant difference in outcomes does not mean there is no difference. Had the study not been redesigned mid trial, results would likely have favored thrombectomy.

Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion | NEJM

The effectiveness of endovascular therapy in patients with stroke caused by basilar-artery occlusion has not been well studied. We randomly assigned patients within 6 hours after the estimated time...

nejm.org
1
22
2
90
Direct to Angio Suite (DTAS) workflow on stroke patient: Admission NIHSS= 16 3 hours since stroke onset LVO suspected Door to reperfusion (Aspiration): 18 minutes NIHSS 24h= 1 Every 30 minutes delay before treatment reduces the chance of a good outcome by 14%
24h Control CT

ALT 24h Control CT

13
1
52
Should we trust CTP in the hyperacute period? @TudorGJovin @SunilAShethMD ? We all know the answer ..
16
19
78
JNIS Latest Content Fernandez-Sanchez, @marcriboj, @_AdnanSiddiqui, @o_arad et al use an in vitro #stroke #thrombectomy model to evaluate the suction force of a novel aspiration catheter bit.ly/3cHXRFJ
1
4
15
ANGIOCAT randomized trial results @ #ISC21: Direct to Angio + flat panel CT in suspected LVO pts (including IVT eligible) leads to almost 30 min reduction in door to reperfusion and better outcomes compared to conventional CT/CTA evaluation. @ManuRequenaRuiz @marcriboj
37
7
130
Defining a Target Population to Effectively Test a Neuroprotective Drug ahajournals.org/doi/10.1161/… The paper explains rational behind inclusion criteria of the APRIL trial. AppToll: Neuroprotection in acute ischemic stroke. How to maximize chances to show clinical benefit

Defining a Target Population to Effectively Test a Neuroprotective Drug | Stroke

Background and Purpose: We aim to identify the subgroup of acute ischemic stroke patients with higher probabilities of benefiting from a potential neuroprotective drug using baseline outcome predic...

ahajournals.org
2
3
Load more